X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

29 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 май 2024 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

09 май 2024 06:30:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 май 2024 06:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

30 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

29 апр 2024 06:30:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

01 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

21 мар 2024 06:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

12 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

09 дек 2023 12:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 дек 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

10 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

09 ноя 2023 06:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

02 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

31 окт 2023 08:00:13 Источник Nasdaq GlobeNewswire